Skip to content
21 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Saturday 21 November 2026

News from the 24 hours to Saturday morning, 21 November 2026.

Tone of the day

+7.0strongly positive
Relevant headlines12of 19 read
Stories7grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was mostly about regulatory progress, with a priority review in the US for its gastric cancer drug and a positive EU opinion for Baxfendy, alongside a new SAP partnership. Some caution came from a weak short-term share price trend and mentions of board changes and AI worries.

What drove it

  • FDA priority review
  • Baxfendy EU opinion
  • SAP partnership

Around this day

DayToneHeadlines
Sun 15 Nov+7.59
Mon 16 Nov+4.56
Tue 17 Nov+9.745
Wed 18 Nov+7.029
Thu 19 Nov+5.523
Fri 20 Nov+8.019
Sat 21 Nov+7.012

7 stories · 12 headlines · strongest first

Pharma and healthcare on 21 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
Sone-Ve, AstraZeneca's gastric cancer drug, receives priority review from the FDA +9.53 headlines today · 16 in all, since 20 November · Several outlets report FDA priority review for AstraZeneca's gastric cancer drug.
+10.0Regulator fast-tracks review of its gastric cancer drug application.AllSci (opens the article) ↗
+10.0US regulator gives accelerated review to its gastric cancer filing.TradingView (opens the article) ↗
+9.2Priority review granted by US regulator for its cancer drug.AD HOC NEWS (opens the article) ↗
AstraZeneca share price moves −0.23 headlines today · 7 in all, since 19 November · Pieces discuss share support levels, pipeline strength and delivery.
+9.7Described as ahead of European peers on growth and pipeline.Yahoo Finance Singapore (opens the article) ↗
−5.0Technical analysis notes sellers dominating near a support level.Traders Union (opens the article) ↗
+1.7Opinion piece on whether product delivery changes investor perception.Kalkine Media (opens the article) ↗
AstraZeneca signs cloud ERP deal with SAP +2.52 headlines today · 9 in all, since 15 November · Outlets report AstraZeneca's cloud partnership with SAP.
+5.0Software firm partnership extends AstraZeneca's technology tie-up.Healthcare Digital (opens the article) ↗
−1.7Cloud contract win offset by board changes and AI worries.AD HOC NEWS (opens the article) ↗
Positive EU opinion for AstraZeneca's Baxfendy +9.21 headline today · A piece covers a positive EU opinion for Baxfendy.
+9.2Favourable European regulatory opinion for its product Baxfendy.Kalkine Media (opens the article) ↗
Saudi Heart Association and AstraZeneca sign MoU +5.01 headline today · The Saudi Heart Association and AstraZeneca signed an MoU on cardiac research and training.
+5.0Cooperation agreement on cardiac research and training in Saudi Arabia.وكالة الأنباء السعودية (opens the article) ↗
AstraZeneca appoints Sandhya Sapra as its lung tumour lead +0.81 headline today · Sandhya Sapra joined AstraZeneca for oncology outcomes research.
+0.8Routine senior hire in oncology research team.Oncodaily (opens the article) ↗
AstraZeneca discusses patient association networking +0.81 headline today · An AstraZeneca executive spoke about working with patient associations.
+0.8Executive comments on engaging patient groups; neutral.jiji press (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 21 November · 589 headlines · 93 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt